Zacks: Analysts Expect Allogene Therapeutics, Inc. (NASDAQ:A

Analysts expect Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) to report ($0.61) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Allogene Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.67). Allogene Therapeutics reported earnings per share of ($0.53) in the same quarter […]

Related Keywords

Raymond James , Rafael Amado , William Blair , Morgan Stanley , Primecap Management Co , Allogene Therapeutics Inc , Goldman Sachs Group Inc , Zacks Investment Research , Norges Bank , Nasdaq , Allogene Therapeutics , Get Rating , Allogene Therapeutic , General Counsel Veer Bhavnagri , Street Corp , Sachs Group , Nasdaq Allo , Allo , Medical , Ratings , Consensus ,